Trial Profile
A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Vorolanib (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions; First in man
- Acronyms DAVIO; DAVIO 1
- Sponsors EyePoint Pharmaceuticals
- 01 Nov 2023 According to an EyePoint Pharmaceuticals media release, subgroup analyses were presented at the EURETINA Congress and the Retina Society Annual Meeting in October.
- 30 Oct 2023 According to an EyePoint Pharmaceuticals media release, company will present interim masked safety data through October 1, 2023 in 173 patients rom the ongoing Phase 2 PAVIA, DAVIO 2 and DAVIO 1 trial.
- 02 Aug 2023 According to an EyePoint Pharmaceuticals media release, twelve-month results of this study will be presented at the European Society of Ophthalmology Congress 2023 in Prague. The presentation marked the first time that EyePoint presented EYP-1901 clinical trial results outside of the U.S.